{
    "clinical_study": {
        "@rank": "131283", 
        "acronym": "PC6", 
        "arm_group": [
            {
                "arm_group_label": "G17DT", 
                "arm_group_type": "Experimental", 
                "description": "250 \u00b5g administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 \u00b5g every 6 months at investigator's discretion."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Compare the effect of G17DT with that of placebo on the survival of subjects with advanced\n      pancreatic cancer."
        }, 
        "brief_title": "Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with a histologically or cytologically confirmed diagnosis of pancreatic\n             carcinoma, who were not eligible for tumor resection with curative intent (i.e.,\n             Stage II, III, or IV disease)\n\n          -  Male or female subjects over 18 years of age\n\n          -  Subjects with a life expectancy of at least 2 months\n\n          -  KPS score of \u226560%\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Previous, concomitant, or anticipated use (up to Week 12) of chemotherapy,\n             radiotherapy, immunotherapy, or any other anticancer therapy\n\n          -  Previous (during the 4 weeks before the study), concomitant, or anticipated use (up\n             to Week 12) of immunosuppressants. However, for systemic [i.e., oral or injected]\n             corticosteroids, previous use and concomitant use at study entry were prohibited,\n             while introduction during the course of the study was permitted.)\n\n          -  History of other malignant tumor within the previous 5 years, except nonmelanomatous\n             skin cancer, and in situ carcinoma of the uterine cervix\n\n          -  Known immunodeficiency\n\n          -  Females who were pregnant, planning to become pregnant, or lactating (Women who, in\n             the opinion of the investigator, were of childbearing potential were to have a\n             negative pregnancy test before study drug administration.)\n\n          -  Subjects taking part in another study involving an investigational or licensed drug\n             or device in the 3 months preceding enrollment or up to Week 12 during this study\n\n          -  Previous G17DT treatment\n\n          -  Hematological indicators as follows:\n\n               -  Hemoglobin <9.5 g/dL\n\n               -  Neutrophils <2.0 \u00d7 109/L\n\n               -  Platelets <100 \u00d7 109/L\n\n          -  Any other condition or circumstance that might have the following results:\n\n               -  Worsen if the subject participated in the study\n\n               -  Reduce the subject's ability to comply with the protocol\n\n               -  Confound the interpretation of the study results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "154", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118077", 
            "org_study_id": "PC6"
        }, 
        "intervention": {
            "arm_group_label": "G17DT", 
            "intervention_name": "G17DT", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 17, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Department of Health"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The vital status of each patient was followed until death or end of the study.", 
                "measure": "Patient Survival", 
                "safety_issue": "Yes", 
                "time_frame": "Up to week 134"
            }, 
            {
                "description": "Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-exisiting illnesses, were assessed at each visit.", 
                "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to week 134"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patients were monitored for an objective tumor response measured by means of an abdomincal computed tomography.", 
            "measure": "Objective tumor response", 
            "safety_issue": "Yes", 
            "time_frame": "Weeks 24 and 52"
        }, 
        "source": "Cancer Advances Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cancer Advances Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}